The boundary between pharmaceutical medicine and performance optimization is blurring rapidly, and therapeutic peptides sit at the center of that shift. For adults navigating obesity, metabolic dysfunction, skin aging, or hormonal decline, understanding which peptide compounds have genuine clinical backing — and which remain experimental — is no longer a niche concern but an urgent practical question.
This systematic review, drawing on 106 studies selected from PubMed, ScienceDirect, and SciELO and weighted toward meta-analyses and randomized controlled trials, maps the clinical evidence for peptides across three distinct domains: metabolic and endocrine disease, aesthetic medicine, and performance enhancement. Approved agents targeting GLP-1, GIP, and related incretin pathways demonstrate robust efficacy for type 2 diabetes and obesity management. Peptide hormone analogs show validated utility in specific endocrine deficiency states. Topical and injectable peptides for skin rejuvenation show early mechanistic plausibility, though human trial data remain thinner. The review explicitly flags a growing category of unapproved compounds infiltrating preventive and longevity medicine, where safety profiles are largely unknown.
This synthesis arrives at a critical moment. The explosion of compounded and gray-market peptides — including growth hormone secretagogues like ipamorelin and CJC-1295, along with BPC-157 and others popularized in longevity circles — has outpaced regulatory oversight and controlled clinical data. While the approved GLP-1 receptor agonists now have substantial phase III trial backing and post-market safety surveillance, most novel peptides lack even phase II human data. The reviewers' cautionary note is well-placed: mechanistic elegance in animal models has repeatedly failed to translate cleanly to human physiology. For health-conscious adults, the practical takeaway is a hierarchy of evidence — lean heavily on the approved agents with replicated trial data, and approach the broader peptide landscape with calibrated skepticism until human safety and efficacy evidence matures.
